IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in IN8BIO, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- +3 vs. Q3 2025
- Shares held
- 3.23M
- +2.25M (+229.3%) vs. Q3 2025
- Total value
- $7.45M
- +$5.32M (+250.3%) vs. Q3 2025
- New holders
- 7
- 7 more added
- Sold out
- 4
- 6 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INAB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 21 | $5.35M |
| Q1 2026 | 19 | $5.55M |
| Q4 2025 | 22 | $7.45M |
| Q3 2025 | 19 | $2.13M |
| Q2 2025 | 12 | $1.83M |
| Q1 2025 | 28 | $3.60M |
| Q4 2024 | 26 | $7.72M |
| Q3 2024 | 26 | $2.06M |
| Q2 2024 | 26 | $6.77M |
| Q1 2024 | 32 | $10.2M |
| Q4 2023 | 30 | $11.4M |
| Q3 2023 | 21 | $2.58M |
| Q2 2023 | 22 | $3.59M |
| Q1 2023 | 17 | $1.78M |
| Q4 2022 | 16 | $2.79M |
| Q3 2022 | 17 | $2.42M |
| Q2 2022 | 15 | $5.50M |
| Q1 2022 | 14 | $7.02M |
| Q4 2021 | 14 | $7.80M |
| Q3 2021 | 13 | $12.2M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding IN8BIO, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 34 | $80 | 0.00% | +34 | New |
| Bank of America Corp | 37 | $87 | 0.00% | +1+2.8% | Added |
| Rockefeller Capital Management L.P. | 83 | $194 | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 84 | $197 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 777 | $1.82K | 0.00% | +762+5,080.0% | Added |
| Jones Financial Companies LLLP | 1,228 | $2.87K | 0.00% | +1,228 | New |
| Tower Research Capital LLC (TRC) | 2,450 | $5.73K | 0.00% | −605−19.8% | Reduced |
| Northwestern Mutual Wealth Management Co | 2,785 | $6.52K | 0.00% | −133−4.6% | Reduced |
| HRT Financial LP | 14,913 | $34.0K | 0.00% | +14,913 | New |
| XTX Topco Ltd | 17,043 | $39.9K | 0.00% | +4,551+36.4% | Added |
| Northern Trust Corp | 17,400 | $40.7K | 0.00% | +17,400 | New |
| Captrust Financial Advisors | 18,295 | $42.8K | 0.00% | +18,295 | New |
| Geode Capital Management, LLC | 20,969 | $49.1K | 0.00% | +1,677+8.7% | Added |
| Texas Capital Bank Wealth Management Services Inc | 23,750 | $55.6K | 0.00% | +23,750 | New |
| Two Sigma Investments, LP | 28,214 | $66.0K | 0.00% | −21,239−42.9% | Reduced |
| Vanguard Group Inc | 28,348 | $66.3K | 0.00% | −31,070−52.3% | Reduced |
| Two Sigma Advisers, LP | 36,351 | $85.1K | 0.00% | −9,400−20.5% | Reduced |
| Stonepine Capital Management, LLC | 164,893 | $385.9K | 0.31% | +5,472+3.4% | Added |
| BIOS Capital Management, LP | 253,417 | $593.0K | 0.72% | −33,247−11.6% | Reduced |
| 683 Capital Management, LLC | 724,637 | $1.70M | 0.14% | +724,637 | New |
| Franklin Resources Inc | 914,531 | $2.05M | 0.00% | +724,637+381.6% | Added |
| Alyeska Investment Group, L.P. | 957,484 | $2.23M | 0.01% | +875,000+1,060.8% | Added |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −26,182−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −24,728−100.0% | Sold out |
| DRW Securities, LLC | 0 | $0 | 0.00% | −18,300−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −49−100.0% | Sold out |